GLP-1 + amylinInvestigational, not FDA-approvedEvidence tier: Small early human trial

Amycretin: Now in Phase 3 — What's Known So Far

Last reviewed November 1, 2026.

Quick answer

Amycretin: a Novo Nordisk compound that acts on both GLP-1 and amylin receptors.

FDA status: Investigational, not FDA-approved. Source: The Lancet .

In a small early trial (phase 1b/2a, 125 people in total), the 36-week injection group had an estimated average weight change of -22.0% vs +1.9% on placebo, estimated as if everyone stayed on treatment.

Last reviewed November 1, 2026 by the PeptideX team. Educational info, not medical advice. PeptideX doesn't give dosing advice. Talk to a licensed clinician.

FDA status: investigational, not FDA-approved. Amycretin, made by Novo Nordisk, is a single molecule that acts on both GLP-1 and amylin receptors. It is being studied as a once-weekly injection and as an oral tablet. A phase 3 trial (AMAZE 1) began in February 2026 [S1][S2][S3].

Quick facts

  • What it is: a Novo Nordisk compound that acts on both GLP-1 and amylin receptors [S1].
  • FDA status: investigational, not FDA-approved [S1].
  • Early trial result: in a small early trial (phase 1b/2a, 125 people in total), the 36-week injection group had an estimated average weight change of -22.0% vs +1.9% on placebo, estimated as if everyone stayed on treatment [S1][S4].
  • Next step: the phase 3 AMAZE 1 trial began in February 2026 [S2][S3].

What the small early trial found

  • Phase 1b/2a, 125 people across several parts, compared with placebo, studied as a once-weekly injection [S1].
  • The 36-week dose-response group: estimated -22.0% vs +1.9% on placebo. Novo and the Lancet report this as an estimate if all participants had followed the trial schedule; many participants withdrew [S1][S4].
  • Small early trials can't show how a medicine works in large groups of people. Phase 3 is testing that [S2].

Results come from separate trials with different people and designs, so they can't be compared directly.

What's next for amycretin

Novo Nordisk started the phase 3 AMAZE 1 trial in February 2026 [S2][S3].

Related: CagriSema (investigational), MariTide (investigational), Orforglipron (Foundayo, FDA-approved).

Questions

Is amycretin FDA-approved?

No. It is investigational and not FDA-approved. A phase 3 trial began in February 2026 [S3].

How much weight did people lose in trials?

In a small early trial, the 36-week injection group had an estimated average weight change of -22.0% vs +1.9% on placebo, estimated as if everyone stayed on treatment [S1].

Is it a pill or an injection?

It is being studied in both forms, as a once-weekly injection and as an oral tablet [S1][S2].

Can I get it?

It is not FDA-approved. Talk with a licensed clinician about your situation, including whether a clinical trial fits you. You can search open studies on ClinicalTrials.gov.

Does PeptideX tell me how to use it?

No. We do not give doses or sourcing.

Educational only. This is not medical advice. Talk with a licensed clinician before starting, stopping or changing any medicine. PeptideX doesn't give dosing advice. This page does not give doses or sourcing. peptidex.ai does not sell drugs or link to sellers. This page was drafted with AI assistance and reviewed against the sources below.

PeptideX is a brand of VitalBridgeX Holdings LLC, a US company.

The PeptideX team

Sources (last reviewed November 1, 2026)